Fjarde AP Fonden Fourth Swedish National Pension Fund Raises Position in Celgene Co. (CELG)

Fjarde AP Fonden Fourth Swedish National Pension Fund increased its position in shares of Celgene Co. (NASDAQ:CELG) by 2.3% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 183,238 shares of the biopharmaceutical company’s stock after acquiring an additional 4,037 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Celgene were worth $26,720,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of CELG. Signature Estate & Investment Advisors LLC grew its position in shares of Celgene by 1.1% in the 3rd quarter. Signature Estate & Investment Advisors LLC now owns 128,883 shares of the biopharmaceutical company’s stock valued at $18,794,000 after buying an additional 1,385 shares during the last quarter. DekaBank Deutsche Girozentrale grew its position in shares of Celgene by 1.0% in the 3rd quarter. DekaBank Deutsche Girozentrale now owns 561,404 shares of the biopharmaceutical company’s stock valued at $73,985,000 after buying an additional 5,700 shares during the last quarter. Sigma Planning Corp grew its position in shares of Celgene by 399.8% in the 3rd quarter. Sigma Planning Corp now owns 19,834 shares of the biopharmaceutical company’s stock valued at $2,892,000 after buying an additional 15,866 shares during the last quarter. Lockheed Martin Investment Management Co. grew its position in shares of Celgene by 40.0% in the 3rd quarter. Lockheed Martin Investment Management Co. now owns 14,000 shares of the biopharmaceutical company’s stock valued at $2,041,000 after buying an additional 4,000 shares during the last quarter. Finally, Montag A & Associates Inc. bought a new stake in shares of Celgene in the 3rd quarter valued at about $1,108,000. Institutional investors and hedge funds own 79.74% of the company’s stock.

Celgene Co. (NASDAQ CELG) opened at $106.00 on Friday. Celgene Co. has a 52 week low of $94.55 and a 52 week high of $147.17. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. The firm has a market capitalization of $83,460.00, a P/E ratio of 25.00, a P/E/G ratio of 0.67 and a beta of 1.77.

Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping analysts’ consensus estimates of $1.87 by $0.04. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The business had revenue of $3.29 billion for the quarter, compared to the consensus estimate of $3.42 billion. During the same period in the prior year, the business earned $1.58 EPS. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. analysts anticipate that Celgene Co. will post 6.69 earnings per share for the current year.

A number of research firms have commented on CELG. Stifel Nicolaus set a $130.00 price target on Celgene and gave the company a “buy” rating in a research report on Monday, January 8th. SunTrust Banks set a $127.00 price target on Celgene and gave the company a “buy” rating in a research report on Monday, January 8th. Guggenheim reiterated a “buy” rating and issued a $147.00 price target on shares of Celgene in a research report on Wednesday. Oppenheimer set a $166.00 price target on Celgene and gave the company a “buy” rating in a research report on Monday, January 8th. Finally, Cantor Fitzgerald set a $112.00 price target on Celgene and gave the company a “hold” rating in a research report on Monday, January 8th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and nineteen have assigned a buy rating to the stock. Celgene currently has a consensus rating of “Buy” and an average price target of $131.18.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by Stock Observer and is owned by of Stock Observer. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.thestockobserver.com/2018/01/14/fjarde-ap-fonden-fourth-swedish-national-pension-fund-raises-position-in-celgene-co-celg.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply